Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206590 | 1.00 | F10 (0.79) | F10 | |
| SCHEMBL5168675 | 0.90 | F10 (0.82) | F10 | |
| SCHEMBL5170336 | 0.89 | F10 (0.81) | F10 | |
| SCHEMBL4482922 | 0.89 | F10 (0.86) | F10 | |
| SCHEMBL4480278 | 0.88 | F10 (1.00) | F10 | |
| SCHEMBL5169151 | 0.88 | F10 (0.79) | F10 | |
| SCHEMBL4481695 | 0.88 | F10 (0.87) | F10 | |
| Formic Acid SCHEMBL4472155 | 0.87 | F10 (0.78) | F10 | |
| SCHEMBL6558100 | 0.87 | F10 (0.85) | F10 | |
| SCHEMBL4467312 | 0.87 | F10 (0.85) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1839659-A2 | Chemicals compounds | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | claimed |
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-07-05 | — | — | US | claimed |
| EP-1395606-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | claimed |
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | claimed |
| EP-1395553-B1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LTD (GB) | 2005-02-16 | — | — | EP | claimed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | claimed |
| EP-1395606-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | claimed |
| EP-1395553-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | claimed |
| WO-2002100830-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | claimed |
| WO-2002100886-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | claimed |
| US-7517879-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-14 | — | — | US | disclosed |
| US-7429587-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7326785-B2 | Pyrrolidine derivatives as factor XA inhibitors | GLAXO GROUP LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| US-7282497-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| EP-1839659-A2 | Chemicals compounds | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
| EP-1395606-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1395553-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002100830-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100886-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | F10 10/4885 |
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | TFPI, F2, SERPINC1 | F10 10/4885 |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | F10 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.